rheumatoid
arthriti
ra
system
autoimmun
diseas
affect
world
popul
ra
typic
character
symmetr
polyarthr
involv
extrem
eros
joint
chang
mediat
hyperplast
synovium
pannu
chronic
inflamm
diseas
sever
associ
elev
product
inflammatori
cytokin
activ
tissu
degrad
proteas
etiolog
ra
incomplet
understood
studi
rodent
ra
model
provid
major
insight
pathophysiolog
ra
includ
discoveri
dysregul
cytokin
signal
network
provid
base
develop
new
treatment
central
role
provid
rational
therapi
target
arthritogen
cytokin
intervent
greatli
improv
diseas
control
qualiti
life
ra
patient
major
patient
achiev
moder
incomplet
diseas
control
remiss
achiev
patient
side
effect
approv
ra
therapeut
limit
use
number
patient
popul
thu
new
efficaci
therapi
need
ra
major
effort
underway
identifi
develop
novel
treatment
strategi
defensin
host
defens
peptid
compos
three
evolutionarili
relat
structur
famili
design
function
antimicrobi
effector
innat
immun
mammal
express
uniqu
old
world
monkey
absent
primat
includ
human
hominid
macrocycl
tridisulfidestabil
acid
molecul
produc
posttransl
headtotail
splice
two
nonapeptid
fig
known
cyclic
polypeptid
anim
conform
confer
remark
stabil
vitro
vivo
six
ten
isoform
produc
rhesu
monkey
baboon
respect
fig
prototyp
therapeut
efficaci
infecti
diseas
model
peptid
highli
effect
reduc
lethal
mice
experiment
sever
acut
respiratori
syndrom
sar
murin
model
e
coli
polymicrobi
sepsi
therapeut
effect
mediat
least
part
modul
proinflammatori
cytokin
vitro
studi
reveal
rtd
suppress
express
secret
proinflammatori
cytokin
includ
tlr
agoniststimul
leukocyt
antiinflammatori
effect
mediat
regul
mapk
signal
pathway
studi
suggest
pleiotrop
peptid
evolv
neutral
pathogen
modul
inflamm
test
concept
evalu
effect
cours
pristaneinduc
arthriti
pia
da
rat
model
autoimmun
arthriti
share
mani
featur
human
ra
base
find
effect
dosedepend
suppress
resolv
pia
conduct
studi
identifi
mechan
may
mediat
therapeut
efficaci
observ
anim
use
approv
univers
southern
california
usc
institut
anim
use
care
committe
protocol
sequenti
blood
sampl
pharmacokinet
analys
perform
bioanalyt
system
inc
basi
west
lafayett
aaalacaccredit
facil
anim
studi
complianc
nation
institut
health
guid
care
use
laboratori
anim
anim
euthan
carbon
dioxid
inhal
confirm
thoracotomi
per
iacuc
guidelin
methotrex
mtx
sigmaaldrich
st
loui
mo
prepar
salin
etanercept
immunex
corp
thousand
oak
ca
obtain
usc
investig
drug
servic
pharmaci
reconstitut
per
manufactur
instruct
hydrochlorid
salt
prepar
previous
report
produc
highli
pure
materi
assess
analyt
reversephas
ultraperform
liquid
chromatographi
rpuplc
tandem
mass
spectrometri
steril
stock
solut
dissolv
normal
salin
store
femal
daolahsd
blood
group
allel
agouti
also
known
dark
agouti
rat
obtain
harlan
laboratori
indianapoli
anim
allow
acclim
hour
prior
experiment
use
anim
fed
standard
chow
ad
lib
daynight
cycl
pia
induc
week
old
anim
gm
intraderm
inject
pristan
sigma
divid
site
base
tail
anim
monitor
daili
diseas
sever
limb
score
use
method
brand
et
al
sever
score
limb
individu
anim
total
give
individu
arthriti
sever
score
rang
zero
normal
anim
maximum
diseas
score
sixteen
diseas
sever
assess
least
two
scorer
interrat
agreement
kappa
valu
determin
use
medcalc
statist
softwar
version
medcalc
softwar
ostend
belgium
three
separ
trial
treatment
also
blind
scorer
statist
differ
blind
unblind
score
treatment
cohort
treatment
salin
vehicl
antiarthrit
agent
random
initi
anim
first
present
administ
subcutan
dose
rang
mgkg
inject
volum
ml
interv
rang
day
qd
everi
seven
day
mtx
administ
mgkg
intraperiton
inject
etanercept
administ
mgkg
subcutan
inject
limb
euthan
anim
preserv
buffer
formalin
decalcifi
embed
section
stain
hematoxylin
eosin
h
e
usc
research
model
patholog
core
microscop
imag
acquir
nikonmicrophot
fxa
spot
imag
captur
softwar
eight
old
male
spragu
dawley
rat
harlan
fit
surgic
implant
jugular
vein
cathet
sequenti
blood
collect
culex
nxt
autom
vivo
sampl
system
basi
west
lafayett
monitor
daili
dissolv
salin
inject
subcutan
mgkg
anim
approxim
blood
collect
peptid
administr
h
inject
blood
collect
vial
contain
plasma
collect
centrifug
plasma
concentr
determin
solid
phase
extract
spe
weak
cation
exchang
oasi
wcx
water
milford
quantit
rpuplc
photodiod
array
pda
detect
electrosprayion
mass
spectrometri
esim
chromatographi
perform
acquiti
hclass
uplc
analyt
pda
detector
use
empow
softwar
water
quantit
mass
spectrometri
perform
post
pda
eluent
use
micromass
quattro
ultima
mass
spectromet
masslynx
water
pharmacokinet
analysi
perform
use
parametr
popul
model
maximum
likelihood
estim
via
em
algorithm
sampl
mlem
implement
adapt
version
pkpd
system
analysi
softwar
biomed
simul
resourc
univers
southern
california
salin
control
mgkg
sc
qd
treat
pia
rat
euthan
day
diseas
onset
ankl
joint
feet
snap
frozen
liquid
pulver
mortar
pestl
describ
one
gram
tissu
powder
extract
ml
ice
cold
mm
sodium
phosphat
mm
nacl
ph
pb
contain
proteas
inhibitor
tablet
complet
ultra
edta
roch
diagnost
gmbh
mannheim
germani
sampl
vortex
second
extract
clarifi
centrifug
supernat
quantifi
elisa
life
technolog
grand
island
ny
fibroblastlik
synoviocyt
fl
isol
enzymat
digest
synovi
tissu
da
rat
pia
previous
describ
cell
wash
suspend
dmem
supplement
fetal
bovin
serum
gibco
grand
island
ny
mgml
lglutamin
sigma
amphotericin
b
sigma
mgml
gentamicin
gibco
overnight
cultur
nonadher
cell
remov
adher
cell
cultur
approxim
confluenc
passag
follow
detach
trypsinedta
min
experi
perform
fl
least
four
passag
fl
invas
assay
vitro
use
matrigelco
insert
transwel
system
becton
dickinson
compani
franklin
lake
nj
previous
describ
briefli
da
rat
fl
confluent
isol
describ
suspend
cellswel
serumfre
dmem
cell
place
upper
compart
matrigelco
insert
ad
final
concentr
lower
compart
contain
complet
medium
fb
plate
incub
hour
upper
surfac
insert
wipe
cotton
swab
remov
noninvad
cell
matrigel
layer
opposit
side
insert
stain
crystal
violet
sigma
total
number
invad
cell
count
magnif
experi
perform
duplic
seven
cell
line
gener
synovi
tissu
individu
da
rat
pia
fl
cultur
plate
cellswel
h
viabil
trypan
blue
stain
medium
replac
fl
incub
final
concentr
ngml
plu
acet
acid
hoac
vehicl
alon
h
incub
fl
cultur
supernat
remov
clarifi
centrifug
analyz
elisa
invitrogen
carlsbad
ca
fl
seed
cellswel
tc
treat
plate
greiner
cell
allow
adher
h
medium
replac
prior
addit
peptid
vehicl
ad
well
final
concentr
cultur
medium
incub
h
fl
cell
number
determin
dna
stain
use
cyquant
cell
prolifer
assay
kit
invitrogen
per
manufactur
instruct
cellular
toxic
determin
measur
releas
lactat
dehydrogenas
ldh
use
cytotox
cytotox
assay
promega
bio
scienc
san
lui
obispo
ca
fl
supernat
assay
perform
replic
analyz
enzymat
inhibit
zinc
metalloproteas
matrix
metalloproteas
mmp
cystein
cathepsin
cat
b
c
h
k
l
v
tabl
activ
measur
releas
fluorogen
peptid
cleav
protnf
r
system
minneapoli
mn
dilut
mm
tri
ph
incub
dissolv
hoac
assay
initi
addit
substrat
final
enzymat
activ
measur
everi
second
h
spectramax
fluoromet
molecular
devic
sunnyval
ca
nm
excit
nm
emiss
inhibit
cat
b
bp
bioscienc
san
diego
ca
cat
c
h
k
l
v
r
system
analyz
well
format
enzymespecif
substrat
per
manufactur
instruct
describ
tabl
activ
enzym
determin
presenc
inhibit
mmp
perform
describ
incub
enzym
valu
calcul
graphpad
prism
graphpad
softwar
san
diego
ca
util
nonlinear
curv
fit
log
inhibitor
versu
respons
variabl
slope
adult
da
spraguedawley
rat
challeng
sc
mgkg
everi
day
inject
everi
day
inject
sever
anim
boost
month
later
prior
serum
plasma
collect
immun
respons
analyz
dot
blot
nitrocellulos
membran
describ
legend
figur
statist
analys
perform
util
graphpad
prism
sampl
popul
test
normal
use
agostino
pearson
omnibu
normal
test
pvalu
gener
parametr
sampl
mean
student
ttest
nonparametr
sampl
median
compar
mannwhitney
utest
number
replic
andor
total
number
anim
shown
figur
legend
within
figur
antiarthrit
effect
test
daolahsd
rat
pia
wellcharacter
model
chronic
ra
anim
evolv
pia
arthriti
sever
score
score
randomli
assign
treatment
group
treat
daili
subcutan
sc
inject
salin
mgkg
day
fig
treatment
significantli
reduc
arthriti
progress
within
h
first
administ
dose
p
fig
treat
rat
markedli
lower
reduct
mean
end
observ
period
compar
vehicl
control
p
fig
addit
complet
resolut
diseas
occur
treat
anim
compar
salin
treat
anim
p
chisquar
fig
treatment
result
restor
limb
function
mobil
typic
respons
shown
supplement
video
joint
vehicletr
pia
rat
show
extens
swell
synovi
hyperplasia
invas
pannu
eros
cartilag
bone
fig
panel
fig
contrast
treatment
markedli
reduc
erythema
swell
affect
joint
fig
panel
dramat
improv
function
weight
bear
video
clinic
improv
rat
correl
preserv
normal
joint
histolog
fig
panel
fig
similar
limb
anim
fig
panel
fig
joint
peptidetr
anim
devoid
synovi
hyperplasia
inflammatori
infiltr
angiogenesi
eros
chang
preserv
normal
architectur
treatment
also
effect
resolv
advanc
pia
rat
near
maximum
diseas
receiv
daili
sc
inject
salin
mgkg
peptid
treatment
continu
diseas
resolut
achiev
treatment
peptid
treatment
produc
rapid
reduct
arthriti
sever
reach
statist
signific
within
hour
start
treatment
p
complet
resolut
clinic
diseas
treat
rat
day
fig
anim
treat
earli
pia
fig
treatment
anim
sever
pia
restor
normal
limb
function
mobil
video
note
diseasefre
interv
rang
week
three
five
treat
anim
relaps
joint
diseas
averag
score
efficaci
treatment
compar
etanercept
etan
methotrex
mtx
first
line
ra
drug
also
studi
rodent
model
arthriti
rat
pia
etan
mtx
limit
progress
arthriti
day
treatment
compar
vehicl
control
fig
treatment
pronounc
effect
treatment
day
either
etan
mtx
p
p
respect
addit
achiev
highest
rate
complet
diseas
resolut
compar
mtx
etan
fig
antiarthrit
effect
pia
dosedepend
reduct
observ
dose
low
mgkg
fig
dose
mgkg
equal
effect
whether
administ
daili
everi
day
fig
analysi
singl
dose
pharmacokinet
pk
sc
administ
reveal
peptid
disposit
best
describ
model
rel
rapid
distribut
clearanc
halflif
mlkgh
h
respect
prolong
termin
elimin
clearanc
mlkghr
halflif
h
fig
pk
paramet
consist
find
highli
stabl
human
rat
plasma
dose
effect
daili
dose
fig
evalu
immunogen
challeng
da
spragu
dawley
rat
serial
daili
sc
inject
mgkg
serum
plasma
sampl
anim
analyz
humor
respons
dot
immunoblot
assay
ig
detect
peptidechalleng
anim
fig
consist
previou
fail
attempt
gener
antibodi
unmodifi
play
central
role
pathogenesi
ra
rodent
arthriti
previou
studi
show
suppress
express
releas
immunestimul
monocyt
therefor
analyz
effect
administr
joint
level
pia
rat
consist
studi
detect
joint
rat
level
markedli
elev
diseas
joint
pia
rat
joint
level
correl
arthriti
sever
score
correspond
limb
pearson
r
p
fig
pia
rat
establish
diseas
treat
sc
day
four
day
mgkg
vehicl
joint
tissu
euthan
anim
analyz
peptid
treatment
reduc
joint
averag
p
fig
coincid
mark
reduct
arthriti
sever
treat
anim
day
treatment
p
fig
pleiotrop
cytokin
also
implic
ra
pathogenesi
induc
differenti
cell
joint
damag
proteas
angiogenesi
synoviocyt
invas
bone
loss
stimul
fl
arthrit
da
rat
dosedepend
induc
product
consist
previou
studi
significantli
inhibit
product
reduct
fl
fig
arthritogen
cytokin
stimul
prolifer
invas
fl
vitro
invas
properti
cell
mediat
correl
eros
joint
chang
ra
pia
therefor
analyz
effect
fl
prolifer
invas
dosedepend
suppress
fl
prolifer
analyz
hour
cultur
fig
effect
result
cytotox
cell
viabil
sampl
also
dosedepend
suppress
fl
invas
matrigelco
insert
fig
invasionsuppress
effect
observ
low
concentr
ngml
highli
reproduc
seven
independ
da
rat
fl
cell
line
fig
potent
extrem
rapid
inhibitor
releas
lpsstimul
leukocyt
base
kinet
effect
hypothes
inhibit
releas
inhibit
convert
enzym
tace
found
potent
inhibitor
well
relat
protnf
sheddas
tabl
addit
studi
current
underway
disclos
rapidli
revers
inhibit
tace
manuscript
prepar
find
inhibit
adam
zinc
metalloproteinas
test
peptid
effect
zinc
matrix
metalloproteinas
mmp
implic
cartilag
degrad
ra
select
inhibit
pathogen
mmp
valu
rang
tabl
parallel
analyz
effect
cystein
proteas
implic
ra
surprisingli
also
inhibit
cystein
cathepsin
b
c
k
l
v
greatest
potenc
cathepsin
k
nm
tabl
cathepsin
k
proteas
primarili
respons
degrad
bone
matrix
osteoclast
data
indic
cross
class
antiproteas
inhibit
activ
matrix
degrad
proteinas
implic
ra
joint
damag
despit
advanc
ra
treatment
past
year
persist
unmet
need
wide
effect
therapi
given
signific
fraction
patient
partial
respond
inelig
candid
exist
drug
previou
studi
disclos
modul
inflammatori
cytokin
express
rodent
infecti
diseas
model
immunestimul
human
leukocyt
studi
arthritogen
cytokin
among
downregul
base
find
hypothes
would
alter
cours
diseas
rodent
model
ra
wherein
diseas
onset
progress
driven
studi
report
employ
rat
pia
sinc
tcell
depend
diseas
model
mimic
human
ra
includ
symmetr
involv
peripher
joint
destruct
cartilag
bone
dysregul
proinflammatori
cytokineschemokin
rheumatoid
factor
posit
chronic
cours
pia
depend
mhc
class
iirestrict
tcell
influenc
nonmhc
gene
produc
cellular
humor
autoimmun
nonmhc
gene
influenc
rat
pia
arthriti
sever
includ
joint
damag
mmp
rat
pia
increasingli
util
model
preclin
evalu
human
ra
drug
candid
report
prototyp
rapidli
arrest
pia
da
rat
peptid
treatment
result
high
rate
diseas
resolut
therapeut
effect
rapid
dose
level
dose
interv
depend
induc
diseas
resolut
effect
inhibitor
mtx
rate
exceed
report
use
mous
antibodi
remiss
rate
observ
treat
ra
patient
moreov
arrest
diseas
progress
resolut
arthriti
obtain
treatment
earli
sever
stage
pia
therapeut
respons
correl
mark
reduct
limb
swell
recoveri
limb
function
mobil
studi
effect
evolv
diseas
resolut
clinic
arthriti
correspond
histolog
joint
morpholog
disclos
treat
anim
essenti
normal
joint
structur
wherea
control
anim
show
sever
pannu
format
chronic
inflamm
eros
fig
fig
studi
perform
histolog
evalu
joint
treat
anim
maximum
establish
diseas
fig
note
peptid
treatment
sever
arthrit
anim
induc
higher
frequenc
complet
clinic
resolut
fig
video
occur
treatment
anim
evolv
diseas
fig
may
translat
signific
sinc
treatment
ra
usual
initi
diseas
well
establish
hypothes
somewhat
paradox
find
reflect
pleiotrop
antiarthrit
mechan
differenti
affect
pathophysiolog
evolv
establish
sever
diseas
studi
underway
identifi
patholog
andor
resolutionpromot
process
modul
differ
stage
pia
evalu
effect
anoth
anim
model
ra
collagen
induc
arthriti
like
provid
addit
insight
antiarthrit
mechan
mediat
data
suggest
modul
arthritogen
pathway
one
level
exampl
downregul
inflammatori
cytokin
express
shown
occur
transcript
posttranscript
level
former
reveal
studi
macrophag
wherein
shown
downregul
map
kinas
activ
inhibit
transcript
posttransl
regul
arthritogen
mediat
exemplifi
rapid
potent
inhibit
block
releas
consist
effect
treatment
pia
rat
suppress
express
joint
central
mediat
arthriti
upregul
also
act
directli
fl
reduc
product
reduc
cell
invas
two
process
involv
joint
damag
studi
underway
delin
pathway
mediat
modul
inflammatoryarthritogen
cytokin
network
implic
ra
inhibitori
action
arthritogen
proteas
includ
mmp
cathepsin
k
suggest
anoth
antiarthrit
mechan
may
oper
vivo
result
current
studi
demonstr
cross
class
antiproteas
inhibit
zinc
metalloproteinas
adam
mmp
cystein
cathepsin
inhibitori
potenc
panel
mmp
cathepsin
vari
substanti
plasma
level
cmax
achiev
follow
sc
treatment
approxim
exceed
cathepsin
k
potenti
provid
rapid
mechan
regul
arthritogen
proteas
former
case
downregul
local
level
downstream
effect
eg
mmp
express
may
also
contribut
inhibit
fl
invas
mediat
low
concentr
express
high
level
leukocyt
tissu
old
world
monkey
howev
absent
hominid
result
pseudogen
precursor
gene
primat
evolut
evid
suggest
express
rhesu
macaqu
neutrophil
underli
superior
antimicrobi
properti
azurophil
granul
cell
compar
human
possess
uniqu
immunomodulatori
properti
lack
human
potenti
contribut
mark
resist
express
monkey
eg
macaqu
vervet
baboon
endotoxin
result
studi
indic
cyclic
peptid
potenti
new
agent
treatment
ra
pharmaceut
candid
natur
occur
molecul
well
toler
administ
subcutan
studi
ref
intraven
intramuscular
intraperiton
rout
unpublish
result
nonimmunogen
fig
circumv
develop
neutral
antibodi
problem
encount
subset
patient
respons
biolog
therapeut
highli
stabl
biolog
matric
unusu
long
termin
halflif
allow
infrequ
dose
fig
show
evid
immunocompromis
concept
use
nonhuman
primat
peptid
repres
novel
retroevolutionari
therapeut
paradigm
wherebi
product
gene
express
old
world
monkey
may
use
treat
human
autoimmun
disord
